Compare Inovio Pharmaceuticals Inc (INO) vs Oscar Health Inc (OSCR) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

Oscar Health (OSCR) trades at $29.60, up 1.72% today, showing mixed signals with a bullish technical trend but bearish oscillators. The company reported revenue growth to $11.70B in 2025, though net income remains negative at -$443.15M. Recent earnings beat expectations in Q1 2026 with EPS of $2.07, while analyst sentiment is divided with a consensus price target of $24.67. Positive cash flow trends and media coverage highlight growth potential amid ongoing profitability challenges.

Outlook: OSCR offers growth exposure in health insurance with strong revenue expansion and cash flow, but profitability risks persist. Investment opportunity lies in execution toward breakeven, while risks include margin pressure and competitive threats. The stock's current price above consensus target suggests cautious optimism is warranted.